Home  »  Finance   »  What Will Oramed Pharmaceuticals Inc. (NASDAQ: ORM...

What Will Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) Be Like In 2022

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares, rose in value on Thursday, 05/12/22, with the stock price up by 6.43% to the previous day’s close as strong demand from buyers drove the stock to $4.14.

Actively observing the price movement in the last trading, the stock closed the session at $3.89, falling within a range of $3.74 and $4.18. The value of beta (5-year monthly) was 1.86. Referring to stock’s 52-week performance, its high was $31.54, and the low was $3.80. On the whole, ORMP has fluctuated by -40.09% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.


As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.16, which is expected to increase to -$0.13 for fiscal year -$0.76 and then to about -$0.94 by fiscal year 2023. Data indicates that the EPS growth is expected to be 2.60% in 2023, while the next year’s EPS growth is forecast to be -23.70%.

Analysts have estimated the company’s revenue for the quarter at $700k, with a low estimate of $700k and a high estimate of $700k. According to the average forecast, sales growth in current quarter could jump up 9.40%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $2.77 million, representing an increase of 2.50% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 1 upward and no downward review(s) in last seven days. We see that ORMP’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ORMP currently trading nearly -26.54% and -45.80% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 25.52, while the 7-day volatility ratio is showing 11.80% which for the 30-day chart, stands at 8.98%. Furthermore, Oramed Pharmaceuticals Inc. (ORMP)’s beta value is 2.02, and its average true range (ATR) is 0.50. The company’s stock has been forecasted to trade at an average price of $27.33 over the course of the next 52 weeks, with a low of $20.00 and a high of $32.00. Based on these price targets, the low is -383.09% off current price, whereas the price has to move -672.95% to reach the yearly target high. Additionally, analysts’ median price of $30.00 is likely to be welcomed by investors because it represents a decrease of -624.64% from the current levels.

A comparison of Oramed Pharmaceuticals Inc. (ORMP) with its peers suggests the former has fared considerably weaker in the market. ORMP showed an intraday change of 6.43% in last session, and over the past year, it shrunk by -59.65%%. In comparison, Sanofi (SNY) has moved higher at 0.99% on the day and was down -2.51% over the past 12 months. On the other hand, the price of Novo Nordisk A/S (NVO) has risen 0.52% on the day. The stock, however, is off 32.27% from where it was a year ago. Additionally, there is a loss of -0.90% for Ultragenyx Pharmaceutical Inc. (RARE) in last trading while the stock has seen an overall depriciation of -52.75%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.13%. Meanwhile, the Dow Jones Industrial Slipped by -0.33%.

Data on historical trading for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) indicates that the trading volumes over the past 3 months, they’ve averaged 561.66K. According to company’s latest data on outstanding shares, there are 37.11 million shares outstanding.

Nearly 3.90% of Oramed Pharmaceuticals Inc.’s shares belong to company insiders and institutional investors own 26.60% of the company’s shares. The stock has fallen by -71.01% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ORMP stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts



Download Free eBook For


100% free. stop anytime no spam